Commodore Capital LP 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Commodore Capital LP disclosed 33 US equity positions worth $1.4bn in its Q2 2025 13F filing. The largest position was MERUS N V at 13.1% of the reported book, followed by NUVALENT INC and XENE. Against the Q1 2025 filing, it opened 7 new positions, added to 9 and reduced 8 among the top 33 holdings.
What did Commodore Capital LP own in Q2 2025? Top 33 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | MERUS N V | 13.1% | $185.4m | 3,525,000 | -21% | reduced | |
| 2 | NUVALENT INC | 7.4% | $104.9m | 1,375,000 | -26% | reduced | |
| 3 | XENE XENON PHARMACEUTICALS INC | Healthcare | 6.7% | $94.7m | 3,025,000 | 30% | added |
| 4 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.6% | $94.1m | 4,692,809 | 0% | held |
| 5 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 5.5% | $77.3m | 2,325,000 | 6% | added |
| 6 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 5.0% | $70.2m | 3,450,000 | 8% | added |
| 7 | ALKS ALKERMES PLC | Healthcare | 4.9% | $70.1m | 2,450,000 | 26% | added |
| 8 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 4.8% | $68.2m | 4,875,000 | 35% | added |
| 9 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 4.2% | $59.4m | 1,075,000 | – | new |
| 10 | CDTX CIDARA THERAPEUTICS INC | 4.0% | $57.2m | 1,175,000 | – | new | |
| 11 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 3.6% | $51.4m | 1,450,000 | -17% | reduced |
| 12 | SLNOEUR SOLENO THERAPEUTICS INC | 3.6% | $51.1m | 610,000 | -47% | reduced | |
| 13 | RLAY RELAY THERAPEUTICS INC | Healthcare | 3.3% | $46.2m | 13,350,000 | – | new |
| 14 | NRIX NURIX THERAPEUTICS INC | Healthcare | 3.2% | $45.0m | 3,948,653 | -1% | reduced |
| 15 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.1% | $43.3m | 3,298,289 | 39% | added | |
| 16 | PHVS PHARVARIS N V | 2.4% | $33.6m | 1,911,433 | 0% | held | |
| 17 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 2.3% | $32.7m | 750,000 | – | new |
| 18 | BRD1EUR MIND MEDICINE MINDMED INC | 2.3% | $32.5m | 5,000,000 | 10% | added | |
| 19 | SYRE SPYRE THERAPEUTICS INC | 2.1% | $29.8m | 1,988,084 | 0% | held | |
| 20 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.1% | $29.7m | 3,100,000 | 226% | added |
| 21 | VERA VERA THERAPEUTICS INC | Healthcare | 1.3% | $18.8m | 800,000 | -69% | reduced |
| 22 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.2% | $17.5m | 7,692,300 | – | new |
| 23 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.2% | $16.6m | 2,311,164 | -74% | reduced |
| 24 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.1% | $15.9m | 1,419,714 | 0% | held |
| 25 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 0.9% | $13.1m | 500,000 | 0% | held |
| 26 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.9% | $12.6m | 290,000 | 0% | held |
| 27 | IKT INHIBIKASE THERAPEUTICS INC | 0.7% | $10.5m | 5,397,488 | 1% | added | |
| 28 | PERCEPTIVE CAP SOLUTIONS COR | 0.6% | $8.0m | 750,000 | 0% | held | |
| 29 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.5% | $7.7m | 1,500,000 | – | new |
| 30 | CBIO CRESCENT BIOPHARMA INC. | 0.5% | $7.3m | 453,686 | – | new | |
| 31 | NGNE NEUROGENE INC | 0.5% | $6.4m | 427,866 | -54% | reduced | |
| 32 | VTGN VISTAGEN THERAPEUTICS INC | 0.2% | $3.1m | 1,575,000 | 0% | held | |
| 33 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.2% | $2.4m | 483,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.